SurVaxM Vaccine Evaluated in Phase 2b Trial for Those With Newly Diagnosed Glioblastoma
KEY TAKEAWAYS
- In the phase 2b SURVIVE clinical trial, participants treated with SurVaxM + standard care showed a median overall survival of 22.8 months vs 20.3 months with placebo + standard care, although the primary endpoint did not reach statistical significance.
- Among the prespecified subgroup aged ≤65 years, treatment with SurVaxM was associated with significantly longer overall and progression-free survival.
- Rates of grade 3 or higher adverse events were similar between treatment groups.
Treatment with SurVaxM (SVN53-67/M57-KLH; MimiVax, Buffalo, NY) combined with standard medical care was associated with numerically longer median overall survival in people with newly diagnosed glioblastoma, although the primary endpoint did not reach statistical significance. A prespecified subgroup of participants aged ≤65 years treated with SurVaxM did show statistically significant improvements in both overall survival and progression-free survival. These findings from the phase 2b SURVIVE (NCT05163080) clinical trial were reported by MimiVax and Roswell Park Comprehensive Cancer Center.
The SURVIVE study included 233 evaluable participants across 11 US centers. Overall survival (OS) was the primary endpoint.
Key Results from SURVIVE
- Median OS was 22.8 months among participants receiving SurVaxM vs 20.3 months among those receiving placebo (HR, 0.75; 95% CI, 0.54 to 1.03; P=.076).
- Among participants aged 65 years or younger, median OS was 24.2 months with SurVaxM vs 20.2 months with placebo (HR, 0.64; 95% CI, 0.44 to 0.93; P=.019).
- In the same subgroup, progression-free survival also favored SurVaxM (HR, 0.64; P=.018), with 12-month progression-free survival rates of 44% vs 24%.
- Grade 3 or higher adverse events occurred in 48% of participants receiving SurVaxM and 46% receiving placebo.
Practical Implications in the Clinic
Treatment with SurVaxM was associated with longer survival measures in the prespecified subgroup aged 65 years or younger. Because the primary overall survival endpoint did not reach statistical significance in the full study population, the subgroup findings should be interpreted in that context and alongside continued follow-up from the SURVIVE trial.
Source
MimiVax, Inc. MimiVax and Roswell Park announce results from phase 2b SURVIVE trial of SurVaxM in newly diagnosed glioblastoma. PR Newswire. Published October 7, 2026. Accessed October 8, 2026. https://www.prnewswire.com/news-releases/mimivax-and-roswell-park-announce-results-from-phase-2b-survive-trial-of-survaxm-in-newly-diagnosed-glioblastoma-302900265.html